MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

A · NYSE

Agilent Technologies, Inc.

Industrials · Biotechnology: Laboratory Analytical Instruments

Reference price$140.54As of Jul 28, 2026
Market capitalization$39.69B
52-week range$108.35–$160.27
S&P 500 portfolio weight0.06%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$135.00-3.9% vs. reference
Average$155.13+10.4% vs. reference
High$180.00+28.1% vs. reference
13 Buy3 Hold0 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportAug 26, 2026Jul 2026
Consensus EPS$1.486 estimates
Expected range$1.43–$1.50Low to high EPS
Oct 2026$6.01Street EPS consensus
Oct 2027$6.59Street EPS consensus
Oct 2028$7.49Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Oct 31, 2025.

MetricCurrentPrior
Revenue+6.7% YoY$6.95B$6.51B
Operating income$1.48B$1.49B
Net income$1.3B$1.29B
Operating cash flow$1.56B$1.75B
Capital expenditures($0.41B)($0.38B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

Zacks

Stryker's Q2 Results Likely to Reflect Recovery of Q1 Deferred Orders

Zacks

DXCM Q2 Results Likely to Reflect Strong G7 & Reimbursement Expansion

Zacks

Can GE HealthCare Sustain Growth in Q2 Amid Persistent Cost Headwinds?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.